RoseWifHat priceROSE

March S&P 500 E-Mini futures (ESH25) are trending down -0.01% this morning as investors adopted a cautious stance ahead of the all-important U.S. jobs report that will help shape the outlook for interest rates. In Wednesday’s trading session, Wall Street’s major indexes ended mixed. eBay (EBAY) surged nearly +10% and was the top percentage gainer on the S&P 500 after Meta Platforms proposed publishing eBay’s listings on Facebook Marketplace to comply with a European Union antitrust order. Also, GE HealthCare Technologies (GEHC) climbed more than +3% and was the top percentage gainer on the Nasdaq 100 after Jeffries upgraded the stock to Buy from Hold with a price target of $103. In addition, Maplebear (CART) gained over +4% after S&P Dow Jones Indices announced that the stock would be added to the S&P MidCap 400 Index next week. On the bearish side, Edison International (EIX) slumped over -10% and was the top percentage loser on the S&P 500 after its Californian subsidiary shut off power to customers due to wildfires. Also, Advanced Micro Devices (AMD) slid over -4% after HSBC downgraded the stock to Reduce from Buy with a $110 price target. The ADP National Employment report released on Wednesday showed that U.S. private nonfarm payrolls rose by 122K in December, down from 146K in November and missing the consensus estimate of 139K. Also, U.S. consumer credit unexpectedly fell -$7.49B in November, weaker than the expected +$10.30B increase and marking the largest decline in 15 months. At the same time, the number of Americans filing for initial jobless claims in the past week unexpectedly fell by -10K to a 10-1/2 month low of 201K, compared with the 214K expected. The minutes of the Federal Open Market Committee’s December 17-18 meeting, released Wednesday, revealed that officials embraced a new approach to rate-cutting in light of heightened inflation risks, opting to proceed more cautiously in the coming months. “Participants indicated that the committee was at or near the point at which it would be appropriate to slow the pace of policy easing,” according to the FOMC minutes. “Almost all participants judged that upside risks to the inflation outlook had increased. As reasons for this judgment, participants cited recent stronger-than-expected readings on inflation and the likely effects of potential changes in trade and immigration policy,” the minutes said. Philadelphia Fed President Patrick Harker stated on Thursday that policymakers are on track to reduce interest rates this year, but the precise timing “will be fully dependent upon the incoming data.” Also, Boston Fed President Susan Collins said a more gradual approach to adjusting interest rates is warranted now as officials face “considerable uncertainty” regarding the economic outlook. In addition, Fed Governor Michelle Bowman said she sees lingering inflation risks and that policymakers should be cautious with additional interest rate cuts. Finally, Fed Governor Christopher Waller said on Wednesday, “The extent of further easing will depend on what the data tell us about progress toward 2% inflation, but my bottom-line message is that I believe more cuts will be appropriate.” Meanwhile, U.S. rate futures have priced in a 93.1% probability of no rate change and a 6.9% chance of a 25 basis point rate cut at the January FOMC meeting. Today, all eyes are focused on the U.S. monthly payroll report, which is set to be released in a couple of hours. Economists, on average, forecast that December Nonfarm Payrolls will come in at 164K, compared to November’s figure of 227K.

Investing in altcoins can be a risky venture, as there are many challenges that investors may face. These challenges can range from market volatility to regulatory uncertainties. Before investing in any altcoin, it is important to understand the risks involved and to carefully consider your investment goals. In this section, we will explore some of the challenges and risks associated with investing in altcoins. 1. Market Volatility: Altcoins are known for their high volatility, which can make them attractive to investors looking for high returns. However, this volatility also means that altcoins can experience significant price fluctuations in a short period of time. For example, in 2017, the price of Bitcoin rose from around $1,000 to nearly $20,000 in just a few months, only to crash back down to around $3,000 by the end of 2018. This kind of volatility can be difficult to predict and can result in significant losses for investors. 2. Lack of Regulation: Unlike traditional investments, such as stocks and bonds, altcoins are not regulated by government agencies. This lack of regulation can make it difficult for investors to assess the risks associated with a particular altcoin. For example, some altcoins may be vulnerable to hacking or other security issues, which could result in the loss of investor funds. Additionally, some altcoins may be used for illegal activities, such as money laundering or drug trafficking, which could lead to regulatory crackdowns and legal issues for investors. 3. Limited Adoption: While some altcoins have gained widespread adoption, many are still relatively unknown and have limited use cases. This limited adoption can make it difficult for investors to assess the potential value of a particular altcoin. For example, a new altcoin that promises to revolutionize the way we conduct financial transactions may be highly speculative and may not be widely adopted by users or businesses. 4. Lack of Liquidity: Altcoins are often traded on smaller, less established exchanges, which can result in low trading volumes and limited liquidity. This lack of liquidity can make it difficult for investors to buy or sell altcoins at a fair price. Additionally, some altcoins may have limited trading pairs, which can make it difficult to exchange them for other cryptocurrencies or fiat currencies. 5. Scams and Fraud: The lack of regulation in the altcoin market has also led to an increase in scams and fraudulent activities. Some altcoins may be created solely for the purpose of defrauding investors, while others may promise unrealistic returns or use deceptive marketing tactics to attract investors. It is important to thoroughly research any altcoin before investing and to be wary of any investment opportunities that sound too good to be true. Investing in altcoins can be a high-risk, high-reward venture. While some investors have made significant profits by investing in altcoins, others have suffered significant losses. Before investing in any altcoin, it is important to carefully consider the risks involved and to thoroughly research the altcoin and its underlying technology. By doing so, investors can make informed decisions and mitigate some of the risks associated with investing in altcoins.

As we look ahead to 2025, several adoption trends for $SONIC are emerging that could significantly influence its trajectory in the cryptocurrency market: - Integration with Social Media: The launch of SonicX, a Web3 TikTok App Layer, is designed to onboard a new wave of users into the blockchain ecosystem. By merging gaming with social media, particularly through platforms like TikTok, $SONIC aims to attract mainstream audiences and facilitate greater interaction with decentralized technologies. This initiative has already garnered attention, with over 120,000 users engaged since its launch. - Increased Trading Activity: Following the recent airdrop aimed at TikTok gamers, $SONIC has seen a notable increase in trading volumes and price appreciation. As of January 5, 2025, the token's price rose by 45% over the week, reflecting heightened interest from retail investors. This trend suggests that as more users become aware of $SONIC through social media campaigns, trading activity may continue to surge. - Strategic Partnerships: Collaborations with established entities like Injective Protocol to create a cross-chain AI hub indicate $SONIC's ambition to expand its ecosystem beyond gaming. These partnerships could enhance its appeal and usability across various applications, driving further adoption. - Market Predictions and Potential Growth: Analysts are optimistic about $SONIC's future, with some forecasts suggesting it could reach $30 by the end of 2025. This potential for significant price appreciation is likely to attract both retail and institutional investors, further boosting adoption. - Technological Advancements: Continuous improvements in the Sonic network—such as enhanced scalability, security, and transaction speeds—are expected to attract more users and developers. As blockchain technology evolves, $SONIC's ability to adapt and innovate will be crucial for its long-term success. - Community Engagement: With a substantial portion of the token supply allocated for community incentives (57%), $SONIC fosters active participation among users. This community-driven approach not only enhances user loyalty but also encourages grassroots promotion of the token. Overall, these trends suggest that $SONIC is well-positioned for substantial adoption in 2025. By leveraging social media integration, strategic partnerships, and community engagement, $SONIC aims to establish itself as a leading player in the evolving cryptocurrency landscape.

The overall feeling in the market has been positive since the close of October 2024. Last month, Bitcoin (BTC) rose above its all-time high and surpassed the 100K mark. Eventually, it fell to $93.5K and rose to $98.9K today. Meanwhile, many investors have already made plenty of gains from the November/December 2024 bull run. Determining the next cryptocurrency to explode might be challenging as most funds are attracted to pumping assets. However, this article will explore the performance of cryptocurrencies with much growth potential, especially before the year runs out. The aim is to identify coins with some potential and help investors and traders make informed decisions about each token. Next Cryptocurrency To Explode Today’s article discusses the performance of potentially explosive cryptos that investors should add to their watchlist. It also includes a special mention of the presale token Solaxy. This new meme coin offers a unique blend of these two dynamics by combining meme coins’ excitement and reward potential with the practical utility of a Layer 2 blockchain solution. 1. Artificial Superintelligence Alliance (FET) FET has solidified its position as a standout performer in the crypto-AI sector, gaining significant attention after a 19.69% price surge over the past week. Moreover, the token continues to show potential for further growth, with its daily chart forming a bullish price action pattern. In the last 24 hours, FET’s price increased by 7.40%, reaching $1.58, while its trading volume spiked by an impressive 92.42% to hit $378.32 million, according to CoinMarketCap. Since early August 2024, FET consolidated around the $0.89 range. However, bullish momentum propelled it to $1.33 within a week before encountering resistance and undergoing a slight correction. Interestingly, this correction formed a rounding top pattern, a technical indicator that suggests the possibility of continued upward momentum.In August, an investor showcased confidence in FET by swapping 255.62 billion Shiba Inu (SHIB) tokens (valued at $3.5 million) for 3.114 million FET after experiencing a 45.9% loss on SHIB. This bold decision underscores growing trust in FET’s potential. If the current rally persists, FET could break past the $1.46 resistance, potentially reaching the $1.72 to $1.85 range in the near term.

Emergent BioSolutions Inc. is a life science company that addresses public health threats, with a portfolio that includes Narcan, a nasal spray for opioid overdoses. The company has let its margins deteriorate and used debt to finance them, eroding shareholder value. The new management team is focused on turning around the situation and could potentially unlock considerable value for new investors. I rate Emergent BioSolutions a "hold" due to the balance of turnaround potential and substantial investment risks.Emergent BioSolutions Inc. (NYSE:EBS) is a life science company that addresses public health threats. The company has developed its flagship product, Narcan, a nasal spray that helps people recover from opioid overdoses. EBS also presents a portfolio that includes infectious disease vaccines and treatments for anthrax, smallpox, botulism poisoning, and Ebola, producing a positive worldwide impact on health and safety. Unfortunately, EBS has let its margins deteriorate and used debt to finance them, which has eroded massive shareholder value over the years. The new management team is set on turning around this situation and could potentially unlock considerable value for new investors. But the stakes are high, so I think a “Hold” rating is appropriate for now. Fallen Angel: Business Overview Emergent BioSolutions is a life science company based in Gaithersburg, Maryland. It was founded in 1998 and specializes in developing treatments for public health threats like infectious diseases, chemical contamination, and opioid overdoses. EBS also provides bioservices to deliver Contract Development and Manufacturing Offerings [CDMO] using three technology platforms: A platform that involves mammalian cells for biologics production. Technologies related to plasma proteins for therapeutic applications. A platform to produce viral vectors to deliver genetic material to the cells.EBS commercial products include Naloxone, commercially known as Narcan, a nasal spray used to treat opioid overdoses. This drug is an inhibitor of the µ-opioid receptor and is one of EBS's most important products. Opioid medication helps manage pain but puts patients at risk of an accidental overdose. In the U.S., approximately 219 people die each day from an opioid overdose. The significant demand for Narcan in the middle of the widespread use and abuse of opioids has made this drug an EBS commercial success. Also, it has significantly impacted society, mitigating the consequences of this epidemic. This drug is sold over the counter [OTC] and reverses the effects of an opioid overdose, like respiratory failure or unresponsiveness. The product is broadly available for the public to ensure immediate access that may allow saving a life endangered by an opioid emergency.The company also offers vaccines such as BioThrax for anthrax, ACAM2000 for smallpox, and Ebanga for a Zaire strain of Ebola. Furthermore, EBS commercializes treatments for infectious illnesses, such as Anthraxil, an antitoxin to treat inhalational anthrax. Also, EBS’s Cyfendus, an antitoxin indicated for post-exposure to anthrax, or Raxibacumab, a human monoclonal antibody prescribed for therapy and preventing inhalational anthrax.Home page Seeking Alpha - Power to Investors Home Healthcare Emergent BioSolutions: High-Risk, High-Reward Strategic Turnaround May 10, 2024 12:35 PM ETEmergent BioSolutions Inc. (EBS) Stock36 Comments Myriam Alvarez profile picture Myriam Alvarez 2.16K Followers Summary Emergent BioSolutions Inc. is a life science company that addresses public health threats, with a portfolio that includes Narcan, a nasal spray for opioid overdoses. The company has let its margins deteriorate and used debt to finance them, eroding shareholder value. The new management team is focused on turning around the situation and could potentially unlock considerable value for new investors. I rate Emergent BioSolutions a "hold" due to the balance of turnaround potential and substantial investment risks. Unos pocos viales de naloxona dentro de una foto de archivo del kit Marvin Samuel Tolentino Pineda/iStock via Getty Images Emergent BioSolutions Inc. (NYSE:EBS) is a life science company that addresses public health threats. The company has developed its flagship product, Narcan, a nasal spray that helps people recover from opioid overdoses. EBS also presents a portfolio that includes infectious disease vaccines and treatments for anthrax, smallpox, botulism poisoning, and Ebola, producing a positive worldwide impact on health and safety. Unfortunately, EBS has let its margins deteriorate and used debt to finance them, which has eroded massive shareholder value over the years. The new management team is set on turning around this situation and could potentially unlock considerable value for new investors. But the stakes are high, so I think a “Hold” rating is appropriate for now. Fallen Angel: Business Overview Emergent BioSolutions is a life science company based in Gaithersburg, Maryland. It was founded in 1998 and specializes in developing treatments for public health threats like infectious diseases, chemical contamination, and opioid overdoses. EBS also provides bioservices to deliver Contract Development and Manufacturing Offerings [CDMO] using three technology platforms: A platform that involves mammalian cells for biologics production. Technologies related to plasma proteins for therapeutic applications. A platform to produce viral vectors to deliver genetic material to the cells. Source: 42nd Annual J.P. Morgan Healthcare Conference Presentation. January 2024. Source: 42nd Annual J.P. Morgan Healthcare Conference Presentation. January 2024. EBS commercial products include Naloxone, commercially known as Narcan, a nasal spray used to treat opioid overdoses. This drug is an inhibitor of the µ-opioid receptor and is one of EBS's most important products. Opioid medication helps manage pain but puts patients at risk of an accidental overdose. In the U.S., approximately 219 people die each day from an opioid overdose. The significant demand for Narcan in the middle of the widespread use and abuse of opioids has made this drug an EBS commercial success. Also, it has significantly impacted society, mitigating the consequences of this epidemic. This drug is sold over the counter [OTC] and reverses the effects of an opioid overdose, like respiratory failure or unresponsiveness. The product is broadly available for the public to ensure immediate access that may allow saving a life endangered by an opioid emergency. Source: 42nd Annual J.P. Morgan Healthcare Conference Presentation. January 2024. Source: 42nd Annual J.P. Morgan Healthcare Conference Presentation. January 2024. The company also offers vaccines such as BioThrax for anthrax, ACAM2000 for smallpox, and Ebanga for a Zaire strain of Ebola. Furthermore, EBS commercializes treatments for infectious illnesses, such as Anthraxil, an antitoxin to treat inhalational anthrax. Also, EBS’s Cyfendus, an antitoxin indicated for post-exposure to anthrax, or Raxibacumab, a human monoclonal antibody prescribed for therapy and preventing inhalational anthrax. Source: Q1 2024 Financial Results Update. May 2024. Source: Q1 2024 Financial Results Update. May 2024. The company also has Vaccinia Immune Globulin [VIG] to manage complications of smallpox vaccines. EBS’s Brincidofovir, known commercially as Tembexa, is an antiviral therapy for smallpox and Botulism antitoxin [BAT] for botulism poisoning. Lastly, EBS’s Reactive Skin Decontamination Lotion Kit [RSDL] is a treatment against chemical threats. Together, these comprise a wide-ranging and well-diversified IP portfolio. Restructuring and Expansion: Turnaround Efforts On May 2, EBS' stock rose 60% in the premarket after the company outperformed the financial estimates for Q1 2024 and announced its plans for restructuring, reducing 300 employees, eliminating 85 job openings, and closing the facilities of Baltimore-Bayview Drug Substance manufacturing and Rockville, Maryland Drug Product. These measures, when implemented, are expected to produce $80 million in annual savings. The company is focusing on debt management and reduction, optimizing operating performance. The new strategies and vision are noticeable under the direction of the newly appointed CEO, Joseph Papa, who emphasizes the necessity of a leaner operation. In the latest earnings call, EBS' executives presented the international expansion strategy as a growth driver, leveraging its innovative portfolio with the support of local partners worldwide. The company highlighted the importance of the Medical Countermeasures [MCM] area, incrementing guidance from $340 million to $490 million due to the EBS' role as a biodefense contractor capable of responding to the constant presence of global threats, including anthrax, smallpox, botulism, Ebola, and chemicals. On the other hand, the company anticipates competition for Narcan from generic products during 2024. Still, it expects that EBS's capabilities to serve the OTC and PIP channels and the strength and reputation of the Narcan brand will allow it to maintain the sales forecast at the predicted levels. According to the executives, the market is growing, and EBS' distribution capacities will enable it to take advantage of long-term opportunities. High-Risk, High-Reward: Valuation Analysis From a valuation perspective, EBS trades at a market cap of about $229.0 million. This stands out because we’re talking about a company with projected yearly revenues of $0.9 to $1.1 billion in 2024. However, the problem is that EBS’s margins are terrible, and this is what the market is undoubtedly discounting. Moreover, the company has approximately $909.2 million in total debt, with $458.4 million maturing in 2025. It’s unclear how EBS will handle such a massive debt repayment or how they will refinance it, and dilution is an ongoing risk for shareholders if they make an equity offering to handle thisNevertheless, looking at it as a whole, the business has an implied enterprise value of roughly $1.1 billion. In my analysis, if the company’s margins recovered to 1) management’s optimistic gross margins targets of 45% and 2) SG&A margins of about 20% in 2020 and 2021, then the stock does seem reasonably cheap. For context, this would imply a “blue skies” scenario where EBS makes 25% in EBIT margins. Moreover, interest payments represented about 8% of total revenues in 2023 and Q1 2024. Thus, in this “ideal” scenario, EBS would have about 17% of EBT margins, implying $153 to $187 million in EBT using management’s 2024 revenue guidance.EBIT matters because EV/EBIT is a commonly used valuation metric for indebted companies, and in the "ideal" scenario, EBS would have an EBIT of $225 to $275 million, implying an EV/EBIT ratio of 5.0 to 4.1, which is relatively undervalued. By comparison, EBS’s sector median EV/EBIT ratio is just 15.3, so there’s considerable potential upside in the "ideal" scenario. On the other hand, EBT matters because having an excess cash flow of $153 to $187 million after interest payments proves Emergent BioSolutions can be a going concern in the "ideal" scenario. Highly Speculative Risks The problem is that there are many assumptions to get EBS to that "ideal" scenario, and these are the underlying risks that new potential investors must accept. However, a larger entity could simply EBS altogether (including its debt) and make this turnaround itself because there’s a compelling opportunity if reaching the "ideal" scenario is feasible. So, at these prices, I think EBS is a potential takeover target, and to the extent management is successful in its turnaround efforts, then I believe the share price will surely follow. Yet, the opposite is equally true because EBS is highly speculative now, and there’s still no straightforward way to improve the company’s margins or tackle the debt problem without significant stock dilution or financing. So, as a potential shareholder, you are betting on the new CEO successfully managing the massive upcoming debt maturities while improving the underlying gross and EBIT margins. The stakes are high because if John Papa succeeds, much shareholder value could be unlocked. Likewise, failure can even lead to bankruptcy or a massively diluting equity offering, leading to substantial shareholder losses. Hence, I think the balanced approach is to rate EBS as a "Hold" in light of its turnaround opportunities and upside potential, as well as the significant risks and uncertainties present today."Hold" Rating: Conclusion Overall, EBS is a company that let its margins deteriorate significantly and relied on debt to finance them. Over time, this destroyed significant shareholder value, but the underlying IP portfolio and business are undoubtedly promising. EBS’s products should continue to generate substantial revenue for many years. If Emergent BioSolutions Inc. management succeeds in its turnaround efforts, investors willing to bet on this will receive a handsome reward. However, the opposite is also true, as failure could lead to substantial shareholder losses. Hence, I think EBS is a high-risk, high-reward "hold" now, but it is certainly worth adding to your watch list.